homoharringtonine derivative (BS-HH-002.SA) / Bensheng Pharma - LARVOL DELTA

Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation. (PubMed, Transl Oncol) - "BS-HH-002 is a newly developed drug with excellent antitumor activity, which resulted from the modification and optimization of the side structure of the homoharringtonine (HHT). Compared to HHT, BS-HH-002 quickly reached high blood concentration after intravenous injection or oral administration, without causing obvious cardiac toxicity. These results indicate that BS-HH-002 is a promising new anti-cancer drug to treat pancreatic and other solid tumors."

Journal • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Hematological Malignancies • Hepatology • Leukemia • Myelodysplastic Syndrome • Oncology • Pancreatic Cancer • Solid Tumor • BCL2 • BCL2L1

A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS (clinicaltrials.gov) - P1; N=66; Not yet recruiting; Sponsor: Shanghai Bensen Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology